Mixed response to osimertinib and the beneficial effects of additional local therapy

Background Although non‐small cell lung cancers (NSCLCs) harboring EGFR mutations initially respond well to EGFR‐tyrosine kinase inhibitors (TKIs), they typically progress after approximately one year. The EGFR T790M mutation is the most common resistance mechanism. NSCLCs with T790M respond well to...

Descripción completa

Detalles Bibliográficos

Autores principales:	Yuki Shinno, Yasushi Goto, Jun Sato, Ryo Morita, Yuji Matsumoto, Shuji Murakami, Shintaro Kanda, Hidehito Horinouchi, Yutaka Fujiwara, Noboru Yamamoto, Yuichiro Ohe
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Wiley 2019-04-01
Colección:	Thoracic Cancer
Materias:	Epidermal growth factor receptor mixed response non‐small cell lung cancer oligoprogressive disease osimertinib
Acceso en línea:	https://doi.org/10.1111/1759-7714.12991
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!